The G ␤␥ -sequestering peptide ␤-adrenergic receptor kinase (␤ARK)ct derived from the G-proteincoupled receptor kinase (GRK)2 carboxyl terminus has emerged as a promising target for gene-based heart failure therapy. Enhanced downstream cAMP signaling has been proposed as the underlying mechanism for increased ␤-adrenergic receptor (␤AR) responsiveness. However, molecular targets mediating improved cardiac contractile performance by ␤ARKct and its impact on G ␤␥ -mediated signaling have yet to be fully elucidated.
studies using genetic mouse models, as well as viral-based cardiac gene delivery strategies, demonstrate that ␤ARKct expression in acutely and chronically failing myocardium rescues performance and improves survival in several experimental HF animal models including postischemic, dilated, and hypertrophic cardiomyopathy. 4 -14 Mechanistically, ␤ARKct improves and restores blunted ␤-adrenergic receptor (␤AR)-mediated contractile responsiveness of normal and failing myocardium in vitro and in vivo. 4 -14 At least in failing myocardium, resensitized ␤AR signaling has been proposed as a major underlying molecular mechanism for the inotropic effects of ␤ARKct, although compartmentalized cAMP-dependent signaling has not yet been determined (reviewed elsewhere 1, 2 ). However, given the negative consequences of chronically enhanced cAMPdependent signaling in HF patients 15, 16 experimentally reflected by the detrimental outcome of mouse models with cardiomyocyte-specific overexpression of ␤AR, 17 Gs, 18 PKA, 19 and phosphatase inhibitor 1, 20 there is legitimate concern about using a gene-based strategy potentially facilitating ␤AR signaling in cardiomyocytes.
Interestingly, it appears ␤ARKct may not be exerting all of its effects directly through GRK2 inhibition, and this is likely attributable to its ability to sequester G ␤␥ . Studies suggest a direct G ␤␥ protein-dependent modulation of voltagedependent Ca 2ϩ channels of the N-(␣1 B ) and P/Q-(␣1 A ) type. 21, 22 More recently, an inhibitory interaction between G ␤␥ proteins and the L-(␣1 A ) type Ca 2ϩ channel (LCC), a critical regulator of basal and ␤AR-stimulated cardiomyocyte performance, has been reported in oocytes. 23 Based on this finding and by virtue of the ability of ␤ARKct to sequester G ␤␥ proteins, the present study focused on cardiac LCC as a molecular target for inhibitory G ␤␥ protein and explored signaling pathways conveying ␤ARKct-mediated enhanced ␤AR responsiveness in adult rat ventricular normal (NCs) and failing (FCs) cardiomyocytes.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Animal Procedures
All animal procedures and experiments were performed in accordance with corresponding institutional guidelines of Thomas Jefferson University and the University of Heidelberg.
Experimental Rat Heart Failure Model, Rat Cardiomyocyte Isolation, and In Vitro Adenoviral Gene Transfer Protocol
Left ventricular adult cardiomyocytes (FCs) were enzymatically isolated from failing rat hearts using an experimental postcryoinfarction heart failure model, and sham-operated animals were used to obtain NCs. 24 To achieve cardiomyocyte ␤ARKct expression in vitro, NCs and FCs were subjected to a second generation replication-deficient serotype 2 ␤ARKct adenovirus (Ad␤ARKct). To control adenoviral transfection efficiency by fluorescence microscopy, Ad␤ARKct expressed ␤ARKct and the green fluorescent protein (GFP) reporter gene under control of two independent cytomegalovirus promoter. Control cells in each group were infected with a corresponding adenovirus carrying the GFP cDNA alone (AdGFP). Our protocol 24 resulted in GFP expression in more than 90% of cells after 24 hours in culture without visible signs of toxicity. For detailed protocols, refer to the Online Methods section.
Cardiomyocyte Contractility, Intracellular Ca 2؉ Transients, and Sarcoplasmic Reticulum Ca 2؉ Load
Twenty-four hours after plating, contractile parameters and intracellular Ca 2ϩ transients in AdGFP and Ad␤ARKct transfected NCs and FCs were obtained by video edge detection and epifluorescent assessment of Fura2-AM signals under basal conditions and isoproterenol stimulation. 25 Recordings were taken under 2-Hz continuous electric stimulation at steady-state levels both at 5 minutes and 30 minutes after isoproterenol stimulation. Sarcoplasmic reticulum (SR) Ca 2ϩ content was immediately assessed after termination of Ca 2ϩ transient measurements by abrupt exposure to Na ϩ /Ca 2ϩ free solution supplemented with caffeine (20 mmol/L). The peak of the caffeineinduced cytosolic Ca 2ϩ rise was used as semiquantitative index of the SR Ca 2ϩ load. 26 For further details on chemical treatments, kinase inhibitors and procedures, see the Online Methods section. previously. 28 Concurrent LDH release was measured with a commercially available kit. For detailed description of the procedures, refer to the Online Methods section.
L-Type Calcium Current Recordings
L-type Ca 2ϩ currents (I Ca ) were recorded in single cardiomyocytes with the whole cell-patch clamp configuration of the MultiClamp 700 amplifier (Molecular Devices, Sunnyvale, Calif). 29, 30 To test the effects of Gb/Gy proteins on I Ca , pipettes were filled with an intracellular solution (20 mmol/L KCL, 100 mmol/L K-Aspartate [DL], 20 mmol/L TEA-Cl, 10 mmol/L HEPES, 4.5 mMMgCl 2 , 4 mmol/L Na 2 ATP, 1 mmol/L Na 2 CrP, 2.5 mmol/L EGTA, pH 7.4 KOH) and recombinant human Gb 3 /Gy 3 (for expression and purification see protocol below) was introduced into the cell via the patch pipette. Procedural details are given in the Online Methods section.
Expression and Purification of Recombinant Human G␤ 3 and Gy 3 Proteins
Human myc-DDK-tagged G␤ 3 and Gy 3 were expressed in HEK293 cells and purified by immunoabsorption. Purity and specificity was confirmed by silver staining and anti-DDK/FLAG staining with an anti-DDK monoclonal antibody as described in details in the Online Methods section.
Western Blotting, Cellular PKA Enzyme Activity, and Assessment of Cellular cAMP Content
Protein expression and site-specific phosphorylation analyses was carried our for GFP, CSQ, ␤ARKct, GRK2, phospholamban (PLB), Ser16-PLB, Thr17-PLB, calmodulin-dependent kinase (CaMK)II, Thr286-CaMKII, troponin (Tn)I, Ser23/24-TnI, S100A4, PKC, p-PKC, extracellular signal-regulated kinase (ERK)1/2, p-ERK1/2, Akt, p-Akt, p38, p-38, ERK5, p-ERK5, and GAPDH, and assessment of cellular PKA enzyme activity and cellular cAMP content was performed with a commercially available nonradioactive PKA kinase and cAMP enzyme immunoassay kit, respectively, from cell (in vitro isoproterenol stimulation for 30 minutes) and tissue lysates as described in details in the Online Methods section.
Ryanodine Receptor and Ca v 1.2 Immunoprecipitation and Ca v 1.2 Back-Phosphorylation With PKA
Immunoprecipitation of ryanodine receptor (RyR)2 and Ca v 1.2␣ 26 and PKA-dependent back phosphorylation of immunoprecipitated Ca v 1.2 31 was carried out as described in details in the Online Methods section to assess RyR2 serine-2808 and serine 2815 phosphorylation levels and interaction between G ␤␥ and Ca v 1.2␣ and PKA-dependent phosphorylation of the Ca v 1.2␣ and Ca v 1.2␤ subunit. For details, see the Online Methods section.
Adeno-Associated Virus Serotype 9 Generation and Systemic In Vivo AAV9 Cardiac-Targeted Gene Transfer Protocol
In vivo cardiac-targeted ␤ARKct expression in normal mouse hearts was obtained by using retro-orbital injection of an adeno-associated virus serotype 9 (AAV9) harboring the ␤ARKct gene driven by a cardiomyocyte-specific CMV-MLC0.26 promoter. AAV9 harboring the GFP gene under the same promoter served as control. Adult male C57/B6 mice (age 12 weeks) were anesthetized with isoflurane (2%) and 200 L of 37°C heated PBS containing either 1ϫ10 11 total viral particles of either AAV9-GFP or AAV9-␤ARKct were injected into the circulation accessing the retroorbital venous plexus via the medial corner of the right eye with a 28G1/2 insulin syringe. For detailed description on AAV9 generation and systemic gene transfer, refer to the Online Methods section.
Isolation of Mouse Heart Cardiomyocyte and Noncardiomyocyte Fraction From AAV9-Transfected Hearts and Echocardiographic Analysis of Cardiac Function
␤ARKct and GFP expression, enzymatic isolation of cardiomyocyte, and noncardiomyocyte fractions and functional assessment in normal mouse hearts 3 were performed 6 weeks after systemic AAV9 application by Western blotting and echocardiography as described in detail in the Online Methods section.
Statistics
Data are generally expressed as meansϮSEM. An unpaired 2-tailed Student t test and 2-way repeated measures ANOVA were performed for statistical comparisons. For all tests, a probability value of Ͻ0.05 was considered as significant.
Results

␤ARKct-Mediated Inotropic Effects in Cardiomyocytes Require Direct ␤AR Stimulation
We first analyzed Ca 2ϩ handling in NCs and FCs subjected either to ␤ARKct (Ad␤ARKct) or control adenovirus (AdGFP). There was a greater increase in Ca 2ϩ transient amplitudes in field-stimulated (2 Hz) ␤ARKct-expressing NCs over control when exposed to the ␤AR agonist isoproterenol ( Figure 1A) . In contrast, both groups responded similarly to the adenylyl cyclase (AC) activator forskolin (FSK). Similar to NCs, direct ␤AR but not AC stimulation triggered a persistent gain-in function in ␤ARKct-expressing FCs over AdGFP ( Figure 1B ). Basally, ␤ARKct did not result in an inotropic effect in NCs or FCs ( Figure 1A and 1B). Results for fractional shortening mirrored this pattern (Table) . In line with our in vitro data, ␤ARKctexpressing mouse hearts, using cardiomyocyte-targeted adenoassociated serotype 9 virus (AAV9) mediated transgene expression, exhibited increased left ventricular fractional shortening compared to controls when stimulated with isoproterenol but not with the AC activator NKH477. Statistical analysis and cardiomyocyte-targeted ␤ARKct expression in NCs and mouse hearts is shown in Online Figure I.
␤ARKct Enhances Ca 2؉ Cycling Independent of SR Ca 2؉ Load and Diastolic RyR2 Function
Given that SR Ca 2ϩ load critically grades the Ca 2ϩ transient amplitude on ␤AR stimulation, 32 we assessed the impact of ␤ARKct on SR Ca 2ϩ content in NCs and FCs. Despite greater Ca 2ϩ transient amplitudes, neither ␤AR-stimulated ␤ARKctexpressing NCs nor FCs showed increased SR Ca 2ϩ load over control ( Figure 1C and the Table) . FSK treatment resulted in the same SR Ca 2ϩ content in corresponding GFP and ␤ARKctexpressing cardiomyocytes (Table) . This observation prompted analysis of diastolic RyR2 function to determine whether ␤ARKct might enhance the diastolic SR Ca 2ϩ leak. However, ␤ARKct neither altered basal (Table) nor ␤AR-mediated increases in frequency ( Figure 1D and ␤ARKct Improves Cardiomyocyte I Ca on ␤AR Stimulation Analysis of steady-state whole cell LCC current I Ca revealed a greater peak I Ca amplitude in ␤AR-stimulated (Figure 2A and 2B) but not FSK (Table) treated ␤ARKct-expressing NCs and FCs compared with GFP cells. A much smaller but still significant difference in basal peak I Ca was also evident between control and ␤ARKct-expressing cardiomyocytes ( Figure 2C and 2D). Additional measurements enabled us to determine a significant difference in voltage-dependent steady-state availability (f ϱ ) that further increased on ␤AR stimulation, whereas I Ca activation (d ϱ ), I Ca time-to-peak and decay constants were not different between groups (Online Figure II ). Subsequent calculation of the maximal steadystate window I Ca (f ϱ ϫd ϱ ) revealed significantly higher values for ␤ARKct-expressing NCs (control Ϸ5% versus Ϸ9% ␤ARKct, PϽ0.05) which is consistent with sustained Ca 2ϩ influx at more depolarized membrane potentials. On ␤AR stimulation, f ϱ ϫd ϱ increased similarly (Ϸ23%) in ␤ARKctexpressing NCs and FCs (data not shown). In keeping with these data, ␤ARKct rendered field-stimulated Ca 2ϩ transients in NCs more susceptible to the use-dependent LCC antagonist nifedipine as reflected by the leftward shift of relative IC50 compared with control (Online Figure II) .
␤ARKct Does Not Alter cAMP-Dependent Kinase Signaling Downstream of Activated ␤ARs
Previous studies described facilitated ␤AR signaling conferring inotropic actions of ␤ARKct (reviewed elsewhere 1,2 ). We therefore investigated both compartmentalized and total PKA activity. There was equal basal and ␤AR-triggered PKA-mediated increases of PLB phosphorylation at serine 16 (PLB-Ser16, shown for 10 Ϫ9 mol/L isoproterenol) both in control and ␤ARKct-expressing NCs and FCs ( Figure 3A ). Similar results were obtained for the sarcomeric PKA target TnI at serine 23/34 (TnI-Ser23/24) and indistinguishable EC50 for isoproterenol-mediated PLB and TnI phosphorylation matched by equal PKA activity in control and corresponding ␤ARKct-expressing cardiomyocytes (Online Figure  III) . We also assayed PKA-dependent changes in phosphorylation of the ␣1C-LCC (Cav1.2␣) ( Figure 3B ), the ␤2C-LCC subunit (data not shown) as well as RyR2 (RyR-Ser2808; Figure  3C ). Basal and PKA-dependent back-phosphorylation of I Ca and site-specific phosphorylation of RyR2 were not different between ␤ARKct-expressing and control NCs and FCs (Figure 3B and 3C) . In further support of a PKA-independent inotropic effect, myr-PKI as well as alternative chemical PKA inhibitors such as Rp-8-Br-cAMPS and H89 (data not shown) blocked the isoproterenol-mediated increase in PLB-Ser16 phosphorylation both in control and ␤ARKctexpressing cardiomyocytes but did not abrogate the relative ␤ARKct-mediated gain-in function (Online Figure IV) . Assessment of cellular cAMP concentrations unveiled a similar increase in their levels both in isoproterenol-stimulated control and ␤ARKct-expressing NCs and FCs with equally blunted ␤AR-induced AC activity in the latter group (Online Figure IV ). We next determined compartmentalized CaMKII activity and activation as downstream target of exchange protein activated by cAMP (Epac). 33 CaMKII-dependent PLB (PLB-Thr17) and RyR2 (RyR2-Ser2815) phosphorylation as well as activated CaMKII (CaMKII-Thr268; Figure Table. FURA2 emission ratios shown in A through C are given as arbitrary units. For cell numbers, see the Table. 4A through 4C) was similar in isoproterenol-stimulated control and ␤ARKct-expressing cardiomyocytes. We also found that isoproterenol had indistinguishable effects on PKC and ERK1/2 phosphorylation levels in ␤ARKctexpressing and control cells (Online Figure VI) as well as on p38, ERK5 and Akt activity (data not shown). Further corroborating a CaMKII-and PKC-independent effect of ␤ARKct, the chemical selective CaMKII and broad-spectrum PKC inhibitor myr-AIP and bisindolylmaleimide-1 (BIM), respectively, equally diminished the isoproterenol-induced increase in the Ca 2ϩ transient amplitude in both groups without abolishing the ␤ARKct-mediated gain in function (data not shown). The CaMKII inhibitor KN93 and its inactive analog KN92 were not used given that both compounds were reported to nonspecifically inhibit Cav1.2␣ activity in a CaMKII-independent manner. 34 
␤ARKct Inhibits G ␤␥ -Mediated Suppression of I Ca in Cardiomyocytes on ␤AR Stimulation
A previous study reported on a direct inhibitory effect of G ␤␥ proteins on cardiac LCC activity through interaction with the cytosolic amino-and carboxyl terminus of the pore-forming Cav1.2␣ subunit. 23 G ␤␥ -sequestering peptides derived either from G␣ i1 or the GIRK1 potassium channel prevented this effect and subsequently enhanced I Ca . Activation of heterotrimeric G proteins by ␤AR agonists in cardiomyocytes is known to release G ␤␥ from activated G␣ subunits. 1 To assess whether G ␤␥ can suppress I Ca in cardiomyocytes, we assayed the effect of recombinant G␤ 3 and G␥ 3 isoforms on basal and ␤AR-stimulated I Ca in voltage-clamped NCs and FCs. G␤ 3 and G␥ 3 were chosen because studies suggest they are the most abundant G ␤␥ protein isoforms in rat adult cardiomyocytes. 35 Application of 30 nmol/L recombinant human G␤ 3 / G␥ 3 suppressed ␤AR-stimulated I Ca both in control NCs and FCs ( Figure 5A and 5B) . G␤ 3 /G␥ 3 -mediated suppression of I Ca was prevented both in NCs and FCs expressing ␤ARKct ( Figure 5C and 5D ). In line with the notion of a potentially rate-limiting concentration of ␤ARKct, increasing G␤ 3 /G␥ 3 concentrations by 10-fold to 300 nmol/L eventually abrogated enhanced I Ca both in ␤ARKct-expressing NCs and FCs ( Figure  5C and 5D ). 3 nmol/L G␤ 3 /G␥ 3 did not have an effect in GFP or ␤ARKct-expressing NCs and FCs (data not shown).
␤ARKct Attenuates G ␤␥ Binding to LCC in Cardiomyocytes on ␤AR Stimulation G␤ binding to Cav1.2␣ is enhanced by ␤AR stimulation in control NCs and FCs compared to basal conditions ( Figure 6A ). ␤ARKct attenuated G␤/Cav1.2␣ interaction resulting in a decrease of G␤/Cav1.2␣ binding ratios in NCs and FCs ( Figure  6A ). We also tested whether recombinantly expressed G␤ 3 /G␥ 3 proteins used for I Ca measurements bound to Cav1.2␣ in extracts of control and ␤ARKct-expressing NCs. 30 nmol/L myc-DDKtagged G␤ 3 /G␥ 3 proteins were added to cellular extracts of isoproterenol-stimulated control and ␤ARKct-expressing NCs. Cav1.2␣/myc-DDK-tagged G␤ 3 coprecipitated in control but not ␤ARKct-expressing NCs ( Figure 6B ). Addition of 300 nmol/L recombinant G␤ 3 /G␥ 3 protein, a concentration that suppressed I Ca in ␤ARKct-expressing cardiomyocytes, resulted in G␤ 3 /␣1C-LCC coprecipitation ( Figure 6B ).
␤ARKct-Mediated Improvement of I Ca Renders Cardiomyocytes Susceptible Neither to Cell Death Nor Arrhythmogenic Diastolic Ca 2؉ Waves
Previous studies demonstrated detrimental effects of chronically enhanced I Ca in cardiomyocytes both with constitutive ␣1C-LCC and ␤2C-LCC subunit overexpression under basal conditions and ␤AR stimulation in vitro. 28, 36 However, cardiomyocytes with ␤ARKct-mediated I Ca enhancement exhibited a trend toward improved survival under basal conditions and isoproterenol treatment for 24 hour compared with corresponding controls (Online Figure VI) . In support of this notion, there was a trend toward greater LDH levels in the supernatant of control cells (Online Figure VI) . Indistinguishable cellular viability was also evident between groups after 24 hour caffeine (1 mmol/L) treatment, which sensitizes RyR2s to cytosolic Ca 2ϩ (Online Figure VI) . Of note, when field-stimulated ␤ARKct-expressing and control NCs and FCs were subjected to a combination of caffeine (0.5 mmol/L) and isoproterenol (10 Ϫ7 mol/L) that has been shown to trigger diastolic Ca 2ϩ waves, 37 ␤ARKct apparently conveyed a protective effect by attenuating the onset of arrhythmogenic Ca 2ϩ waves (Online Figure VII) .
Discussion
Among other targets, 2 ␤ARKct has emerged as a promising candidate for gene-based therapy targeting abnormal ␤AR responsiveness in failing myocardium. 4 -14 Our study characterizes a G ␤␥ -based molecular mechanism that attenuates cardiac LCC/I Ca in normal and diseased cardiomyocytes on ␤AR stimulation. Targeted interruption of this inhibitory pathway by ␤ARKct results in I Ca disinhibition and improved ␤AR contractile responsiveness. Mechanistically, this action is based on the ability of ␤ARKct to sequester G ␤␥ proteins (summarized in Figure 7 ). Apparently, this mechanism seems neither to require nor rely on cAMP-dependent kinase signaling. These results might have both physiological and clinical implications as they advance the molecular understanding of ␤ARKct toward a cAMP-independent inotrope and, at the same time, provide novel insight into a G ␤␥ -based mechanism in cardiomyocytes negatively shaping I Ca on ␤AR stimulation. Of note, ␤ARKct-mediated improvement of I Ca rendered cardiomyocytes neither susceptible to SR Ca 2ϩ overload nor diastolic Ca 2ϩ leakage or enhanced ␤ARinduced cell damage.
Enhanced I Ca As Potential Mechanism for Inotropic Effects of ␤ARKct in Cardiomyocytes
Given that I Ca constitutes one of the dominant factors in controlling cardiac inotropy, 32, 38 enhancing I Ca on ␤AR stimulation appears as a potent means to grade cardiomyocyte performance. This is reflected by augmented ␤AR-mediated contractile responsiveness in ␤ARKct-expressing NCs exhibiting increased I Ca in response to isoproterenol treatment. Our data suggest that a similar mechanism is in effect in FCs yielding blunted I Ca increase on ␤AR stimulation. The latter has been considered as common pathophysiological feature in FCs across several experimental HF models and human failing cardiomyocytes. 39 Reversal of this defect seems to be key for ␤ARKct to restore cytosolic Ca 2ϩ handling and ␤AR contractile responsiveness in our experimental setting. The rather modestly enhanced basal I Ca on the other hand did not translate into heightened contractile performance and Ca 2ϩ cycling in ␤ARKct-expressing cardiomyocytes. Although counterbalancing outward currents carried by potassium (I K ) remain inactivated in the voltage-clamped mode, 39 they are active under field stimulation and likely candidates to effectively antagonize ␤ARKct-mediated moderate enhancement of basal inward I Ca . Hence, at least in this study, biologically relevant amplification of cardiac I Ca by ␤ARKct seems to be limited to and requires direct ␤AR stimulation both in normal and diseased rat cardiomyocytes.
Our data reveal that the inotropic effect of ␤ARKct is attributable to a larger steady-state window I Ca based on greater LCC availability. Previous studies suggest that sustained I Ca can result in progressive Ca 2ϩ load in cardiomyocytes potentially compromising contractile performance and cellular viability. 28 In addition, progressive SR Ca 2ϩ load can also render cardiomyocytes susceptible to arrhythmogenic Ca 2ϩ abnormalities. 40 Our data however reveal that ␤ARKct-mediated I Ca enhancement does not lead to SR Ca 2ϩ overload with subsequent diastolic Ca 2ϩ leakage and exaggerated cell death. This suggests that ␤ARKct-expressing cardiomyocytes can avoid these potentially fatal consequences by balancing increased systolic I Ca through augmented diastolic Ca 2ϩ efflux under steady-state conditions. This can potentially be accomplished in part by altered sodium/calcium exchanger activity or alternative mechanisms, which will be a subject for future studies. Conclusively, our results provide novel mechanistic insight and identify I Ca as significant mechanism conferring inotropic actions of ␤ARKct on ␤AR stimulation -potentially through a G ␤␥ -based mechanism as further discussed below.
Role of cAMP-Dependent Signaling for Inotropic Effects of ␤ARKct
The differential effect of ␤ARKct on I Ca and SR function prompted further investigations of Ca 2ϩ handling proteins with respect to their ultimate role as molecular effectors of ␤AR downstream signaling. 32 Because of recent reports highlighting the necessity to determine site-specific phosphorylation of cAMP-dependent kinase targets, 41, 42 we assessed both PKA-and CaMKII-dependent activity at distinct sarcoplasmic, sarcomeric and sarcolemmal targets which more accurately reflect transient and compartmentalized cAMP gradients than global cellular cAMP measurements. In line with previously reviewed data, 43, 44 control experiments revealed abnormal ␤AR downstream signaling in FCs compared with NCs. Our results unveiled indistinguishable PKAand CaMKII-dependent phosphorylation patterns at different subcellular sites in ␤ARKct-expressing and control normal and diseased cardiomyocytes closely reflecting similar changes in SR Ca 2ϩ load and diastolic RyR2 function on ␤AR stimulation. Unchanged EC50 values for distinct PKAdependent targets as well as total PKA activity and cellular cAMP levels further corroborate the conclusion that ␤ARKct-mediated enhanced ␤AR contractile responsiveness Data were normalized to Iso-stimulated control NCs (AdGFP). B, Representative immunoblots for immunoprecipitated Cav1.2␣ from cellular extracts of Iso-stimulated NCs (10 Ϫ7 mol/L) with addition of 30 nmol/L myc-DDK-G␤ 3 demonstrate coprecipitation of myc-DDK-G␤ 3 and endogenous G␤ in control NCs that is prevented in extracts of ␤ARKct-expressing NCs (left). However, a 10-fold increase in myc-DDK-G␤ 3 (300 nmol/L) results in Cav1.2␣/myc-DDK-G␤ 3 coprecipitation. Similar results were obtained for myc-DDK-G␥ 3 and endogenous G␥ (data not shown). Cells for immunoprecipatation (IP) were derived from 4 different isolations. Each IP (nϭ4) was carried out in duplicates. Data are shown as meansϮSEM. Iso was used at 10 Ϫ7 mol/L. and Ca 2ϩ cycling in our setting is neither based on nor requires enhanced cAMP-dependent downstream signaling at least under in vitro conditions. Importantly, unchanged PKAdependent phosphorylation of LCC subunits as well as unaltered CaMKII activity render both cAMP-dependent kinases less likely candidates conveying ␤ARKct-mediated changes in I Ca . 45 Extending our signaling analysis into alternative cAMPindependent signaling pathways downstream of activated ␤ARs unmasked an identical pattern. ␤ARKct did not alter PKC and ERK1/2 or Akt, ERK5 or p38 activation. Although PKC and ERK1/2 have been implicated in cAMPindependent CaMKII activation 33 and ␤-arrestin/metalloproteinase transactivated EGPR-mediated cardioprotection, 46 whereas the GRK2 carboxyl terminus including the ␤ARKct sequence has been shown to inhibit Akt, 47 our data do not support a role for those kinases in ␤ARKct inotropic actions in our experimental setting. Though Akt activity is unchanged in our experimental setting, inhibition of PI3K␥ can exert similar effects on I Ca on ␤AR stimulation than ␤ARKct 48 and future studies need to determine whether these effects might be mechanistically linked. Collectively, our in vitro data support the conclusion that short-term inotropic effects of ␤ARKct in normal and diseased cardiomyocytes are independent of "classical" cAMP-related and alternative kinase-dependent signaling pathways downstream of activated ␤ARs.
Role of G ␤␥ Protein-Related Signaling for Inotropic Effects of ␤ARKct
Studies have pointed toward a role of G ␤␥ proteins in regulating ion channel activity 21 including voltage-dependent Ca 2ϩ channels of the N-(␣1 B ) and P/Q-(␣1 A ) type. 22 Potentially relevant for cardiac I Ca regulation, Dascal and colleagues recently provided evidence that G ␤␥ can bind to the cytosolic Cav1.2␣ amino-and carboxyl terminus of the LCC as expressed in full subunit composition in an oocyte system. 23 This interaction attenuated I Ca and coexpression of G ␤␥ sequestering peptides prevented the inhibitory G ␤␥ /Cav1.2␣ interaction thus disinhibiting I Ca . Herein, we describe for the first time an interaction between G ␤␥ and Cav1.2␣ both in NCs and FCs. It is tempting to speculate that agonist-occupied ␤ARs either coupled to Gs or Gi, 1 are a likely source for "inhibitory" G ␤␥ release potentially reflecting an intrinsic negative feedback mechanism that could limit the increase in I Ca on ␤AR stimulation in normal and failing myocardium although the G protein source remains to be determined.
Targeted interruption of this signaling by ␤ARKct apparently decrease the inhibitory interaction between liberated G ␤␥ and Cav1.2␣ leading to enhanced and restored blunted ␤AR-stimulated I Ca in NCs and FCs by virtue of its ability to sequester G ␤␥ proteins. Our data might also rejuvenate interest into previously reported inotropic effects of other G ␤␥ sequestering peptides in cardiomyocytes such as the amino- (1) .Our results indicate that G ␤␥ can bind to the LCC and attenuate ␤AR-triggered systolic Ca 2ϩ influx potentially functioning as a negative-feedback mechanism (1). B, The G ␤␥ -sequestering ␤ARKct peptide can attenuate the inhibitory interaction between G ␤␥ and LCC (2), thereby preventing G ␤␥ -mediated I Ca suppression on ␤AR stimulation. Our data suggest that I Ca disinhibition (3) could significantly contribute to ␤ARKct-mediated enhancement of ␤AR contractile responsiveness. Our study further indicates that inotropic actions of ␤ARKct neither rely on enhanced PKA nor CaMKII (not shown) signaling and occur independent of SR Ca 2ϩ load. Under steady-state conditions when Ca 2ϩ influx matches Ca 2ϩ efflux, it is tempting to speculate that ␤ARKct-mediated I Ca enhancement during systole is balanced by augmented diastolic Ca 2ϩ extrusion reflected by unchanged net SR Ca 2ϩ load. Further studies need to clarify this issue.
terminal truncated phosducin. 49 In line with our molecular data, ␤ARKct-expressing cardiomyocytes exhibited greater sensitivity to the use-dependent LCC blocker verapamil indicating a higher dependency on LCC activity and PKA inhibitors only blunted the PKA-dependent but not G ␤␥dependent ␤ARKct-mediated increase in Ca 2ϩ transient amplitudes on ␤AR stimulation. Similarly, CaMKII and PKC inhibitors were equally ineffective in abolishing the ␤ARKctmediated gain in function. Together with our signaling data, these results strongly suggest that ␤ARKct conveys its inotropic actions both in NCs and FCs, at least in vitro, by sequestering inhibitory G ␤␥ proteins, which does not translate into augmented cAMP-dependent downstream signaling.
Implications and Limitations of the Study
Our results provide evidence for a mechanism effective both in normal and diseased cardiomyocytes linking ␤ARKctmediated enhancement of ␤AR responsiveness to a G ␤␥dependent pathway that operates independent of cAMPdownstream signaling. Consistent with our data showing unchanged cellular cAMP levels between controls and ␤ARKct-expressing cells basally and in response to shortterm ␤AR stimulation, first studies describing superior ␤ARmediated contractile responsiveness in mice with cardiomyocyte-restricted ␤ARKct expression already demonstrated similar increases in AC activity and cAMP formation in vivo as control mice. 8, 50 These studies therefore pointed toward a potential cAMP-independent mechanism underlying ␤ARKct-mediated enhanced ␤AR contractile responsiveness. Our current study, which systematically assessed ␤AR downstream signaling beyond cAMP therefore advances our understanding by demonstrating that neither enhanced PKA nor CaMKII signaling accounts for improved ␤AR-mediated contractile responsiveness in ␤ARKct-expressing normal and failing rodent cardiomyocytes. Although most reports, 4 -14 including ours, use selective ␤AR agonists, a recent study reported on rather subtle inotropic changes in ␤ARKctexpressing isolated murine cardiomyocytes when exposed to norepinephrine. 51 As the latter stimulates both ␣ARs and ␤ARs which exerts inhibitory and stimulatory effects on I Ca , respectively, 45 it is possible that selective ␤AR stimulation might provide a "biased" picture of th inotropic potency of ␤ARKct. It might be less effective in the context of endogenous catecholamines and future studies on ␤ARKct are needed using epinephrine and norepinephrine in experimental HF models approximating human cardiovascular physiology and structure to address this clinically relevant implication.
It is currently unclear why the previously demonstrated ability of ␤ARKct to inhibit G ␤␥ -dependent GRK2 activity in molecular assays 4 -14 is not translated into facilitated downstream AC signaling both in normal and diseased adult ventricular cardiomyocytes in our short-term experimental setting. However, previous studies have used assessment of AC-mediated cAMP formation in myocardial homogenates and membrane preparations and found enhanced cAMP formation. 4, 52, 53 However, this methodological approach neither adequately reflects cellular cAMP homeostasis nor downstream signaling in subcellular domains in intact cardiomyocytes. Our study is the first to systematically deter-mine this in ␤ARKct-expressing adult normal and diseased cardiomyocytes. Notably, although our results are obtained in a short-term in vitro setting, they indicate that G ␤␥ -dependent mechanisms might coexist with GRK2 inhibition through which ␤ARKct can improve ␤AR contractile responsiveness independent of cAMP-dependent kinase signaling. This concept may be consistent with the idea that inhibition of GRK2 resensitizes ␤ARs on the membrane thus allowing for more signaling through heterotrimeric G proteins on ␤AR stimulation. Sequestration of liberated G ␤␥ through ␤ARKct may in turn disinhibit I Ca through the ␤AR-dependent mechanism described in this study, potentially leading to enhanced ␤AR contractile responsiveness without increasing cAMP formation.
Precise understanding of how this potentially cAMPindependent mechanism translates into therapeutic mechanisms that eventually result in adaptive events with secondarily improved AC activity and cAMP homeostasis is currently limited by the in vitro design of our study. Future in vivo studies are needed to delineate the relative contribution and time line of ␤ARKct effects on G ␤␥ -mediated regulation of I Ca and ␤AR sensitivity by dissecting early and late molecular effects in ␤ARKct-expressing failing hearts and isolated cells. In addition, our study is further limited by the fact that we are currently unaware of other potential G ␤␥dependent cardiac targets of ␤ARKct. Potential interference of ␤ARKct, ie, with nucleoside disphosphate kinase-mediated regulation of G ␤␥ -dependent signaling in cardiomyocytes 54, 55 is just one potential candidate. This highlights the need for a more comprehensive approach to identify ␤ARKct targets which are involved in its inotropic actions and eventually translate into previously reported therapeutic effects.
Given comprehensive evidence for the therapeutic benefit of ␤AR blockers such as metoprolol or carvedilol in clinical practice, it is clear that ␤ARKct-based gene therapy can only be considered as an adjuvant approach to ␤AR blockers. Previous studies in small experimental HF models already suggested potential synergistic and/or additive therapeutic benefits using both metoprolol and ␤ARKct-based gene therapy in a rat HF model. Given that ␤AR blocker therapy protects from sympathetic overdrive but does not result in complete ␤AR blockade, ␤AR-dependent ␤ARKct effects are most likely partially preserved in HF on ␤AR blocker therapy. However, these data have to be viewed with caution as long as such benefit needs to be shown in large-animal HF models, which more closely approximate human cardiovascular physiology.
Conclusion
In summary, our study identifies a G ␤␥ -dependent signaling pathway attenuating cardiomyocyte I Ca on ␤AR as molecular target for the G ␤␥ -sequestering peptide ␤ARKct. Targeted interruption of this inhibitory pathway by ␤ARKct potentially confers improved ␤AR contractile responsiveness through increased I Ca rather than increased or restored cAMP downstream signaling (summarized in Figure 7 ). This potentially unveils a new perspective on ␤ARKct toward cAMPindependent effects on cardiac performance and sheds new light on therapeutic strategies that improve ␤AR responsiveness in failing myocardium.
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